Aura Biosciences (AURA) reported financial results for the second quarter ended June 30, 2026, with a net loss of $45.6 million, compared with $27.0 million a year earlier. The company said cash, cash equivalents and marketable securities totaled $323.8 million at quarter-end.
The company said its Phase 3 CoMpass trial of bel-sar in early choroidal melanoma is fully enrolled with 108 patients, exceeding its enrollment target, and topline data remain on track for the second half of 2027. Aura also announced a restructuring, including a workforce reduction of about 20%, and said its cash runway is expected to extend into the first half of 2029.
- Research and development expenses rose to $30.7 million from $22.9 million in the year-ago quarter.
- General and administrative expenses increased to $17.3 million from $5.7 million, including $10.3 million of stock-based compensation.
- Net loss per common share, basic and diluted, was $0.48, compared with $0.47 a year earlier.
- Aura is deprioritizing its NMIBC program to focus resources on ocular oncology.
- The company appointed Susan Abu-Absi as chief operating officer, Erica Kratz as chief regulatory and quality officer, and Julie Person as chief people officer.
$AURA Insider Trading Activity
$AURA insiders have traded $AURA stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $AURA stock by insiders over the last 6 months:
- LOS PINOS ELISABET DE (See Remarks) sold 47,648 shares for an estimated $241,098
- CONOR KILROY (See Remarks) has made 0 purchases and 2 sales selling 23,817 shares for an estimated $143,399.
- JANET JILL HOPKINS (Chief Medical Officer) sold 20,401 shares for an estimated $103,229
- ANTHONY S GIBNEY (See Remarks) sold 12,824 shares for an estimated $82,330
- MARK PLAVSIC (Chief Technology Officer) sold 15,890 shares for an estimated $80,244
- AMY ELAZZOUZI (Senior Vice President, Finance) sold 8,549 shares for an estimated $43,257
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$AURA Hedge Fund Activity
We have seen 56 institutional investors add shares of $AURA stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 1,121,034 shares (+31.3%) to their portfolio in Q2 2026, for an estimated $7,959,341
- BALYASNY ASSET MANAGEMENT L.P. added 557,654 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,730,705
- MILLENNIUM MANAGEMENT LLC added 480,289 shares (+77.8%) to their portfolio in Q1 2026, for an estimated $3,213,133
- DECHENG CAPITAL LLC removed 360,483 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,411,631
- STATE STREET CORP added 258,314 shares (+26.8%) to their portfolio in Q2 2026, for an estimated $1,834,029
- CALIGAN PARTNERS LP added 229,864 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,537,790
- FRANKLIN RESOURCES INC removed 125,697 shares (-5.7%) from their portfolio in Q1 2026, for an estimated $840,912
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
